<?xml version="1.0"?>
<rss version="2.0">
 <channel>
  <title>StreetInsider.com News Articles</title>
  <link>http://www.streetinsider.com</link>
  <description>Latest StreetInsider.com News Articles</description>
  <language>en-us</language>
  <copyright>Copyright 2026, StreetInsider.com</copyright>
  <managingEditor>rss@streetinsider.com (SI RSS)</managingEditor>
  <webMaster>rss@streetinsider.com (SI RSS)</webMaster>
  <lastBuildDate>Fri, 16 Oct 2026 03:15:13 -0400</lastBuildDate>
  <docs>http://blogs.law.harvard.edu/tech/rss</docs>
  <image>
   <url>http://www.streetinsider.com/images/rss_logo.gif</url>
   <title>StreetInsider.com News Articles</title>
   <link>http://www.streetinsider.com</link>
   <width>143</width>
   <height>28</height>
  </image>
  <skipHours>
   <hour>0</hour>
   <hour>1</hour>
   <hour>2</hour>
   <hour>3</hour>
   <hour>21</hour>
   <hour>22</hour>
   <hour>23</hour>
  </skipHours>
  <skipDays>
   <day>Saturday</day>
   <day>Sunday</day>
  </skipDays>
  <item>
   <title>William Blair Starts Kardigan Inc (KARD) at Outperform</title>
   <link>http://www.streetinsider.com/New+Coverage/William+Blair+Starts+Kardigan+Inc+%28KARD%29+at+Outperform/27194816.html</link>
   <description>&lt;p&gt;William Blair analyst Alethia Young initiates coverage on Kardigan Inc (NASDAQ: KARD) with a Outperform rating.&lt;/p&gt;&lt;p&gt;The analyst comments: “We are initiating coverage of Kardigan with an Outperform rating, and our DCF-based valuation is $38 per share. Kardigan is a clinical-stage cardiovascular company that applies precision medicine and AI-enabled cardiac data to develop first-in-class therapies for heart diseases with no approved treatments. Its lead programs are danicamtiv (genetic DCM), ataciguat (moderate CAVS), and tonlamarsen (acute severe hypertension). Many members from Kardigan are from MyoKardia and have deep experience in precision cardiovascular and developed mavacamten and danicamtiv. Key risks are clinical and</description>
   <guid isPermaLink="true">http://www.streetinsider.com/New+Coverage/William+Blair+Starts+Kardigan+Inc+%28KARD%29+at+Outperform/27194816.html</guid>
   <pubDate>Fri, 16 Oct 2026 03:15:13 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">KARD</category>
   	  </item>
  <item>
   <title>William Blair Starts Kardigan Inc (KARD) at Outperform</title>
   <link>http://www.streetinsider.com/Analyst+Comments/William+Blair+Starts+Kardigan+Inc+%28KARD%29+at+Outperform/27194816.html</link>
   <description>&lt;p&gt;William Blair analyst Alethia Young initiates coverage on Kardigan Inc (NASDAQ: KARD) with a Outperform rating.&lt;/p&gt;&lt;p&gt;The analyst comments: “We are initiating coverage of Kardigan with an Outperform rating, and our DCF-based valuation is $38 per share. Kardigan is a clinical-stage cardiovascular company that applies precision medicine and AI-enabled cardiac data to develop first-in-class therapies for heart diseases with no approved treatments. Its lead programs are danicamtiv (genetic DCM), ataciguat (moderate CAVS), and tonlamarsen (acute severe hypertension). Many members from Kardigan are from MyoKardia and have deep experience in precision cardiovascular and developed mavacamten and danicamtiv. Key risks are clinical and</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Analyst+Comments/William+Blair+Starts+Kardigan+Inc+%28KARD%29+at+Outperform/27194816.html</guid>
   <pubDate>Fri, 16 Oct 2026 03:15:13 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">KARD</category>
   	  </item>
  <item>
   <title>UBS Starts Kardigan Inc (KARD) at Buy</title>
   <link>http://www.streetinsider.com/New+Coverage/UBS+Starts+Kardigan+Inc+%28KARD%29+at+Buy/27173112.html</link>
   <description>&lt;p&gt;UBS analyst Alice Nettleton initiates coverage on Kardigan Inc (NASDAQ: KARD) with a Buy rating and a price target of $25.00.&lt;/p&gt;&lt;p&gt;The analyst comments: “We initiate coverage of Kardigan (KARD) with a Buy rating and $25 PT. Led by the former MyoKardia team, KARD is building a precision cardiology franchise that currently includes three Phase 2 programs, with readouts expected in 1H27: danicamtiv (dani) in genetic dilated cardiomyopathy (DCM), ataciguat (ATA) in calcific aortic valve stenosis (CAVS), and tonlamarsen (TLA) in acute severe hypertension (ASH). Our valuation is primarily driven by dani and ATA, which we estimate can generate 2035 risk-adjusted</description>
   <guid isPermaLink="true">http://www.streetinsider.com/New+Coverage/UBS+Starts+Kardigan+Inc+%28KARD%29+at+Buy/27173112.html</guid>
   <pubDate>Mon, 12 Oct 2026 02:22:02 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">KARD</category>
   	  </item>
  <item>
   <title>UBS Starts Kardigan Inc (KARD) at Buy</title>
   <link>http://www.streetinsider.com/Analyst+Comments/UBS+Starts+Kardigan+Inc+%28KARD%29+at+Buy/27173112.html</link>
   <description>&lt;p&gt;UBS analyst Alice Nettleton initiates coverage on Kardigan Inc (NASDAQ: KARD) with a Buy rating and a price target of $25.00.&lt;/p&gt;&lt;p&gt;The analyst comments: “We initiate coverage of Kardigan (KARD) with a Buy rating and $25 PT. Led by the former MyoKardia team, KARD is building a precision cardiology franchise that currently includes three Phase 2 programs, with readouts expected in 1H27: danicamtiv (dani) in genetic dilated cardiomyopathy (DCM), ataciguat (ATA) in calcific aortic valve stenosis (CAVS), and tonlamarsen (TLA) in acute severe hypertension (ASH). Our valuation is primarily driven by dani and ATA, which we estimate can generate 2035 risk-adjusted</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Analyst+Comments/UBS+Starts+Kardigan+Inc+%28KARD%29+at+Buy/27173112.html</guid>
   <pubDate>Mon, 12 Oct 2026 02:22:02 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">KARD</category>
   	  </item>
  <item>
   <title>Form  4          Kardigan, Inc.            For: Sep 29  Filed by: Reinke Kristin Marie K</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Kardigan%2C+Inc.++++++++++++For%3A+Sep+29++Filed+by%3A+Reinke+Kristin+Marie+K/27137481.html</link>
   <description>si-local-file:///var/storage/secattach/20261001/27137481.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Kardigan%2C+Inc.++++++++++++For%3A+Sep+29++Filed+by%3A+Reinke+Kristin+Marie+K/27137481.html</guid>
   <pubDate>Thu, 01 Oct 2026 18:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">KARD</category>
   	  </item>
  <item>
   <title>Form  3          Kardigan, Inc.            For: Sep 29  Filed by: Reinke Kristin Marie K</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Kardigan%2C+Inc.++++++++++++For%3A+Sep+29++Filed+by%3A+Reinke+Kristin+Marie+K/27137462.html</link>
   <description>si-local-file:///var/storage/secattach/20261001/27137462.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Kardigan%2C+Inc.++++++++++++For%3A+Sep+29++Filed+by%3A+Reinke+Kristin+Marie+K/27137462.html</guid>
   <pubDate>Thu, 01 Oct 2026 17:58:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">KARD</category>
   	  </item>
  <item>
   <title>Form  SCHEDULE 13D/A  Kardigan, Inc.                         Filed by: PERCEPTIVE ADVISORS LLC</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Kardigan%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+PERCEPTIVE+ADVISORS+LLC/27136640.html</link>
   <description>si-local-file:///var/storage/secattach/20261001/27136640.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Kardigan%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+PERCEPTIVE+ADVISORS+LLC/27136640.html</guid>
   <pubDate>Thu, 01 Oct 2026 16:36:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">KARD</category>
   	  </item>
  <item>
   <title>Form  8-K        Kardigan, Inc.            For: Sep 29</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Kardigan%2C+Inc.++++++++++++For%3A+Sep+29/27125616.html</link>
   <description>si-local-file:///var/storage/secattach/20260930/27125616.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Kardigan%2C+Inc.++++++++++++For%3A+Sep+29/27125616.html</guid>
   <pubDate>Wed, 30 Sep 2026 08:02:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">KARD</category>
   	  </item>
  <item>
   <title>Kardigan names Google finance VP to its board of directors</title>
   <link>http://www.streetinsider.com/Board+Changes/Kardigan+names+Google+finance+VP+to+its+board+of+directors/27125499.html</link>
   <description>

&lt;p&gt;Kardigan, Inc. (Nasdaq: KARD), a clinical-stage cardiovascular drug company, has appointed Kristin Reinke to its board of directors, effective September 29, 2026. Reinke will serve as chair of the Audit Committee.&lt;/p&gt;

&lt;p&gt;Reinke is currently vice president of finance at Google, where she leads the application of artificial intelligence to the company's finance organization. She has been a member of Google's finance leadership team since 2005, holding roles in global financial planning and analysis, capital allocation, and controllership. She previously held leadership positions at Oracle and began her career at Arthur Andersen. She also serves as an independent director and audit committee</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Board+Changes/Kardigan+names+Google+finance+VP+to+its+board+of+directors/27125499.html</guid>
   <pubDate>Wed, 30 Sep 2026 08:00:16 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">KARD</category>
   	  </item>
  <item>
   <title>Kardigan Announces Appointment of Kristin Reinke to its Board of Directors</title>
   <link>http://www.streetinsider.com/Press+Releases/Kardigan+Announces+Appointment+of+Kristin+Reinke+to+its+Board+of+Directors/27125475.html</link>
   <description>
&lt;p&gt;    SOUTH SAN FRANCISCO, Calif. &amp;amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Kardigan™, Inc. (Nasdaq: KARD) (“Kardigan”), a precision cardiovascular company, announced today the appointment of Kristin Reinke to its Board of Directors, where she will serve as chair of the Audit Committee. As part of the Board’s public company evolution, Doug Giordano will be stepping down from the Board. Both Ms. Reinke’s appointment and Mr. Giordano’s departure are effective as of September 29, 2026.&lt;/p&gt;&lt;p&gt;“Kristin's proven track record leading AI-driven transformation at global scale will be a great asset to help us achieve our mission of changing the future of</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Kardigan+Announces+Appointment+of+Kristin+Reinke+to+its+Board+of+Directors/27125475.html</guid>
   <pubDate>Wed, 30 Sep 2026 08:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">KARD</category>
   	  </item>
  <item>
   <title>Kardigan Announces Appointment of Kristin Reinke to its Board of Directors</title>
   <link>http://www.streetinsider.com/Business+Wire/Kardigan+Announces+Appointment+of+Kristin+Reinke+to+its+Board+of+Directors/27125475.html</link>
   <description>
&lt;p&gt;    SOUTH SAN FRANCISCO, Calif. &amp;amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Kardigan™, Inc. (Nasdaq: KARD) (“Kardigan”), a precision cardiovascular company, announced today the appointment of Kristin Reinke to its Board of Directors, where she will serve as chair of the Audit Committee. As part of the Board’s public company evolution, Doug Giordano will be stepping down from the Board. Both Ms. Reinke’s appointment and Mr. Giordano’s departure are effective as of September 29, 2026.&lt;/p&gt;&lt;p&gt;“Kristin's proven track record leading AI-driven transformation at global scale will be a great asset to help us achieve our mission of changing the future of</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Kardigan+Announces+Appointment+of+Kristin+Reinke+to+its+Board+of+Directors/27125475.html</guid>
   <pubDate>Wed, 30 Sep 2026 08:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">KARD</category>
   	  </item>
  <item>
   <title>Kardigan Inc (KARD) PT Lowered to $46 at JPMorgan</title>
   <link>http://www.streetinsider.com/Analyst+PT+Change/Kardigan+Inc+%28KARD%29+PT+Lowered+to+%2446+at+JPMorgan/26971276.html</link>
   <description>JPMorgan analyst Anupam Rama lowered the price target on Kardigan Inc (NASDAQ: KARD) to $46.00  (from $51.00) while maintaining a Overweight rating.</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Analyst+PT+Change/Kardigan+Inc+%28KARD%29+PT+Lowered+to+%2446+at+JPMorgan/26971276.html</guid>
   <pubDate>Tue, 25 Aug 2026 08:28:16 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">KARD</category>
   	  </item>
  <item>
   <title>Form  SCHEDULE 13G  Kardigan, Inc.                         Filed by: GIANAKAKOS ANASTASIOS</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Kardigan%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+GIANAKAKOS+ANASTASIOS/26923119.html</link>
   <description>si-local-file:///var/storage/secattach/20260813/26923119.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Kardigan%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+GIANAKAKOS+ANASTASIOS/26923119.html</guid>
   <pubDate>Thu, 13 Aug 2026 19:07:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">KARD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.71573107</category>
   	  </item>
  <item>
   <title>Form  SCHEDULE 13G  Kardigan, Inc.                         Filed by: GIANAKAKOS ANASTASIOS</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Kardigan%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+GIANAKAKOS+ANASTASIOS/26923119.html</link>
   <description>si-local-file:///var/storage/secattach/20260813/26923119.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Kardigan%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+GIANAKAKOS+ANASTASIOS/26923119.html</guid>
   <pubDate>Thu, 13 Aug 2026 19:07:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">KARD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.71573107</category>
   	  </item>
  <item>
   <title>Form  SCHEDULE 13G  Kardigan, Inc.                         Filed by: Edelberg Jay</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Kardigan%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+Edelberg+Jay/26923033.html</link>
   <description>si-local-file:///var/storage/secattach/20260813/26923033.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Kardigan%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+Edelberg+Jay/26923033.html</guid>
   <pubDate>Thu, 13 Aug 2026 18:23:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">KARD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.71573107</category>
   	  </item>
  <item>
   <title>Form  SCHEDULE 13G  Kardigan, Inc.                         Filed by: Edelberg Jay</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Kardigan%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+Edelberg+Jay/26923033.html</link>
   <description>si-local-file:///var/storage/secattach/20260813/26923033.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Kardigan%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+Edelberg+Jay/26923033.html</guid>
   <pubDate>Thu, 13 Aug 2026 18:23:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">KARD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.71573107</category>
   	  </item>
  <item>
   <title>Form  10-Q       Kardigan, Inc.            For: Jun 30</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Kardigan%2C+Inc.++++++++++++For%3A+Jun+30/26901307.html</link>
   <description>
&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://archive.fast-edgar.com/20260811/A52ZK22FZZ2RH9Z2229G2ZYKMTBIZZ22XI82&quot;&gt;http://archive.fast-edgar.com/20260811/A52ZK22FZZ2RH9Z2229G2ZYKMTBIZZ22XI82&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;
Filed on: August 11, 2026
&lt;/p&gt;
</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Kardigan%2C+Inc.++++++++++++For%3A+Jun+30/26901307.html</guid>
   <pubDate>Tue, 11 Aug 2026 07:11:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">KARD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.71573107</category>
   	  </item>
  <item>
   <title>Form  10-Q       Kardigan, Inc.            For: Jun 30</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Kardigan%2C+Inc.++++++++++++For%3A+Jun+30/26901307.html</link>
   <description>
&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://archive.fast-edgar.com/20260811/A52ZK22FZZ2RH9Z2229G2ZYKMTBIZZ22XI82&quot;&gt;http://archive.fast-edgar.com/20260811/A52ZK22FZZ2RH9Z2229G2ZYKMTBIZZ22XI82&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;
Filed on: August 11, 2026
&lt;/p&gt;
</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Kardigan%2C+Inc.++++++++++++For%3A+Jun+30/26901307.html</guid>
   <pubDate>Tue, 11 Aug 2026 07:11:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">KARD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.71573107</category>
   	  </item>
  <item>
   <title>Form  8-K        Kardigan, Inc.            For: Aug 11</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Kardigan%2C+Inc.++++++++++++For%3A+Aug+11/26901143.html</link>
   <description>si-local-file:///var/storage/secattach/20260811/26901143.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Kardigan%2C+Inc.++++++++++++For%3A+Aug+11/26901143.html</guid>
   <pubDate>Tue, 11 Aug 2026 07:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">KARD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.71573107</category>
   	  </item>
  <item>
   <title>Form  8-K        Kardigan, Inc.            For: Aug 11</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Kardigan%2C+Inc.++++++++++++For%3A+Aug+11/26901143.html</link>
   <description>si-local-file:///var/storage/secattach/20260811/26901143.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Kardigan%2C+Inc.++++++++++++For%3A+Aug+11/26901143.html</guid>
   <pubDate>Tue, 11 Aug 2026 07:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">KARD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.71573107</category>
   	  </item>
  <item>
   <title>Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates</title>
   <link>http://www.streetinsider.com/Press+Releases/Kardigan+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Business+Updates/26901065.html</link>
   <description>
&lt;p class=&quot;bwalignc&quot;&gt;
&lt;i&gt;Continued to advance the development of three late-stage programs, supported by the Prolaio platform, aimed at addressing cardiovascular diseases where no approved treatments exist&lt;/i&gt;

&lt;/p&gt;&lt;p class=&quot;bwalignc&quot;&gt;
&lt;i&gt;Danicamtiv KINSHIP-DCM Phase 3 Cohort 1 enrollment now underway; Phase 2b topline data expected 1H 2027&lt;/i&gt;

&lt;/p&gt;&lt;p class=&quot;bwalignc&quot;&gt;
&lt;i&gt;Strong cash position of $661 million following recent IPO extends runway through multiple data readouts and initiation of Phase 3 clinical trials&lt;/i&gt;

&lt;/p&gt;
&lt;p&gt;    SOUTH SAN FRANCISCO, Calif. &amp;amp; PRINCETON, N.J.--(BUSINESS WIRE)--
Kardigan™, Inc. (Nasdaq: KARD) (“Kardigan” or “the Company”), a clinical-stage precision therapeutics company developing medicines that target the root causes of cardiovascular diseases with no approved treatments,</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Kardigan+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Business+Updates/26901065.html</guid>
   <pubDate>Tue, 11 Aug 2026 07:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">KARD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.71573107</category>
   	  </item>
  <item>
   <title>Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates</title>
   <link>http://www.streetinsider.com/Business+Wire/Kardigan+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Business+Updates/26901065.html</link>
   <description>
&lt;p class=&quot;bwalignc&quot;&gt;
&lt;i&gt;Continued to advance the development of three late-stage programs, supported by the Prolaio platform, aimed at addressing cardiovascular diseases where no approved treatments exist&lt;/i&gt;

&lt;/p&gt;&lt;p class=&quot;bwalignc&quot;&gt;
&lt;i&gt;Danicamtiv KINSHIP-DCM Phase 3 Cohort 1 enrollment now underway; Phase 2b topline data expected 1H 2027&lt;/i&gt;

&lt;/p&gt;&lt;p class=&quot;bwalignc&quot;&gt;
&lt;i&gt;Strong cash position of $661 million following recent IPO extends runway through multiple data readouts and initiation of Phase 3 clinical trials&lt;/i&gt;

&lt;/p&gt;
&lt;p&gt;    SOUTH SAN FRANCISCO, Calif. &amp;amp; PRINCETON, N.J.--(BUSINESS WIRE)--
Kardigan™, Inc. (Nasdaq: KARD) (“Kardigan” or “the Company”), a clinical-stage precision therapeutics company developing medicines that target the root causes of cardiovascular diseases with no approved treatments,</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Kardigan+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Business+Updates/26901065.html</guid>
   <pubDate>Tue, 11 Aug 2026 07:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">KARD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.71573107</category>
   	  </item>
  <item>
   <title>Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates</title>
   <link>http://www.streetinsider.com/Press+Releases/Kardigan+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Business+Updates/26901065.html</link>
   <description>
&lt;p class=&quot;bwalignc&quot;&gt;
&lt;i&gt;Continued to advance the development of three late-stage programs, supported by the Prolaio platform, aimed at addressing cardiovascular diseases where no approved treatments exist&lt;/i&gt;

&lt;/p&gt;&lt;p class=&quot;bwalignc&quot;&gt;
&lt;i&gt;Danicamtiv KINSHIP-DCM Phase 3 Cohort 1 enrollment now underway; Phase 2b topline data expected 1H 2027&lt;/i&gt;

&lt;/p&gt;&lt;p class=&quot;bwalignc&quot;&gt;
&lt;i&gt;Strong cash position of $661 million following recent IPO extends runway through multiple data readouts and initiation of Phase 3 clinical trials&lt;/i&gt;

&lt;/p&gt;
&lt;p&gt;    SOUTH SAN FRANCISCO, Calif. &amp;amp; PRINCETON, N.J.--(BUSINESS WIRE)--
Kardigan™, Inc. (Nasdaq: KARD) (“Kardigan” or “the Company”), a clinical-stage precision therapeutics company developing medicines that target the root causes of cardiovascular diseases with no approved treatments,</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Kardigan+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Business+Updates/26901065.html</guid>
   <pubDate>Tue, 11 Aug 2026 07:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">KARD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.71573107</category>
   	  </item>
  <item>
   <title>Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates</title>
   <link>http://www.streetinsider.com/Business+Wire/Kardigan+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Business+Updates/26901065.html</link>
   <description>
&lt;p class=&quot;bwalignc&quot;&gt;
&lt;i&gt;Continued to advance the development of three late-stage programs, supported by the Prolaio platform, aimed at addressing cardiovascular diseases where no approved treatments exist&lt;/i&gt;

&lt;/p&gt;&lt;p class=&quot;bwalignc&quot;&gt;
&lt;i&gt;Danicamtiv KINSHIP-DCM Phase 3 Cohort 1 enrollment now underway; Phase 2b topline data expected 1H 2027&lt;/i&gt;

&lt;/p&gt;&lt;p class=&quot;bwalignc&quot;&gt;
&lt;i&gt;Strong cash position of $661 million following recent IPO extends runway through multiple data readouts and initiation of Phase 3 clinical trials&lt;/i&gt;

&lt;/p&gt;
&lt;p&gt;    SOUTH SAN FRANCISCO, Calif. &amp;amp; PRINCETON, N.J.--(BUSINESS WIRE)--
Kardigan™, Inc. (Nasdaq: KARD) (“Kardigan” or “the Company”), a clinical-stage precision therapeutics company developing medicines that target the root causes of cardiovascular diseases with no approved treatments,</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Kardigan+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Business+Updates/26901065.html</guid>
   <pubDate>Tue, 11 Aug 2026 07:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">KARD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.71573107</category>
   	  </item>
  <item>
   <title>Form  SCHEDULE 13G/A  Kardigan, Inc.                         Filed by: FMR LLC</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Kardigan%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+FMR+LLC/26889378.html</link>
   <description>si-local-file:///var/storage/secattach/20260807/26889378.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Kardigan%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+FMR+LLC/26889378.html</guid>
   <pubDate>Fri, 07 Aug 2026 11:17:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">KARD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.71573107</category>
   	  </item>
 </channel>
</rss>
